Inclusion Criteria:

          -  A histologically or pathologically confirmed diagnosis of AML based on WHO
             classification with or without extramedullary disease except for central nervous
             system disease.

          -  ECOG performance status ≤ 2

          -  Left ventricular ejection fraction (LVEF) ≥ 50%

          -  Female patients of childbearing potential must have a negative pregnancy test < 1 week
             prior to enrollment.

          -  Ability to understand and willingness to sign a written informed consent document.

        Exclusion Criteria:

          -  Patients receiving any other investigational agents or immunotherapy

          -  Patients who have received prior chemotherapy for AML with the exception of
             hydroxyurea or leukapheresis for leukocytosis; prior hypomethylating or
             immunomodulatory agents for MDS are allowed

          -  Previous allo-HSCT of any kind

          -  Active, uncontrolled infection including known hepatitis B or C

          -  Active autoimmune disease and chronic inflammatory conditions requiring concurrent use
             of any systemic immunosuppressants or steroids.

          -  History of any other active cancer diagnosis

          -  Pregnant women

          -  Known HIV-infected patients